Kamada, which produces plasma-derived protein therapeutics, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company's shares are already listed on the Tel Aviv Stock Exchange under the symbol KMDA. The Ness Ziona, Israel-based company, which was founded in 1990 and booked $73 million in sales for the 12 months ended 12/31/2012, plans to list on the NASDAQ under the symbol KMDA. The company initially filed confidentially on 1/24/13. Morgan Stanley and Jefferies & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.
